keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/29150360/changes-in-the-epidemiology-and-distribution-of-the-hepatitis-c-virus-genotypes-in-north-eastern-spain-over-the-last-35-years
#1
Doroteo Acero Fernández, María José Ferri Iglesias, María Buxó Pujolràs, Carmen López Nuñez, Isabel Serra Matamala, Xavier Queralt Molés, Xavier Aldeguer Manté
BACKGROUND: Genotypic distribution and epidemiology of HCV infection in Western Europe countries has changed over the last decades. AIM: To establish the local genotypic profile and characterize the associated demographic variables. MATERIAL AND METHOD: All the genotyping from 1988 to 2015 were considered. Associated demographic variables were included in logistic regression models. Genotyping was carried out with updated commercial kits. RESULTS: Genotype 1b was the most prevalent (42...
November 14, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29149205/kir-content-genotypes-associate-with-carriage-of-hepatitis-b-surface-antigen-e-antigen-and-hbv-viral-load-in-gambians
#2
Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C Whittle, Sarah L Rowland-Jones, Robert Walton
BACKGROUND: Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation...
2017: PloS One
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#3
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#4
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29141246/evaluation-of-temporal-virological-responses-to-interferon-%C3%AE-2b-plus-ribavirin-among-genotype-3a-hepatitis-c-virus-infected-patients
#5
Abida Raza, Muhammad Ovais, Hafsa Aziz, Asim Anwar, Javaid Irfan, Irshad Ahmad, Muhammad Mukhtar
OBJECTIVES: The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a individuals. METHODS: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day-1, and >60 kg 1,200 day-1). The patients received this combination therapy for 24 weeks...
November 16, 2017: Intervirology
https://www.readbyqxmd.com/read/29138492/the-antigenic-variability-of-hcv-in-viral-hla-ag-binding-is-related-to-the-activation-of-the-host-immune-response
#6
P Muñoz de Rueda, S M Jiménez-Ruiz, R Quiles, E J Pavón-Castillero, J A Muñoz-Gámez, J Casado, A Gila, A Ruiz-Extremera, J Salmerón
Our previous data show that hepatitis C virus (HCV) genotype 1 patients expressing the HLA-DQB1 * 0301 allele have a combined response probability of 69%, while the remaining 31% do not respond, probably because the HCV immunodominant epitope (IE) against the DQB1 * 0301 allele is mutated. HCV IE (region sequenced in NS3 is a region encoding aa 1253-1272) from 37 patients (21 Sustained Virological Response, SVR; 16 non-SVR) HLA-DQB1 * 0301+, were analysed by pyrosequencing. In vitro cultures were also determined by CD4+ proliferation, using non-mutated IE (wild-type synthetic peptide) and synthetic mutated peptide...
November 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29138264/comprehensive-investigation-of-cytokine-and-immune-related-gene-variants-in-hbv-associated-hepatocellular-carcinoma-patients
#7
Fengxue Yu, Xiaolin Zhang, Suzhai Tian, Lianxia Geng, Weili Xu, Ning Ma, Mingbang Wang, Yuan Jia, Xuechen Liu, Junji Ma, Yuan Quan, Chaojun Zhang, Lina Guo, Wenting An, Dianwu Liu
Background & Aims: Host genotype may be closely related to the different outcomes of Hepatitis B virus (HBV) infection. To identify the association of variants and HBV infection, we comprehensively investigated the cytokine and immune related gene mutations in patients with HBV associated hepatocellular carcinoma (HBV-HCC). Methods: Fifty-three HBV-HCC patients, 53 self-healing cases (SH) with HBV infection history and 53 healthy controls (HC) were recruited, the whole exon region of 404 genes were sequenced at > 900x depth...
November 14, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/29137590/a-closing-chapter-hepatitis-c-genotype-3-elimination-in-liver-transplant-sofosbuvir-daclatasvir-in-a-hard-to-treat-population
#8
Eva Maria Teegen, Brigitta Globke, Eckart Schott, Johann Pratschke, Dennis Eurich
OBJECTIVES: Historically, hepatitis C virus genotype 3 infection has not been as hard to treat as genotype 1 using interferon-based therapy. Now, genotype 3 infection can be treated using interferon-free regimes such as the combination of sofosbuvir and daclatasvir, which is a highly successful and reliable therapeutic option before liver transplant. However, real world data are rather limited regarding the use of antivirals (sofosbuvir/daclatasvir) for hepatitis C virus genotype 3 recurrence after liver transplant...
November 15, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29135370/pharmacokinetics-based-adjusted-versus-standard-dose-of-ribavirin-does-not-improve-virologic-response-rates-in-chronic-hepatitis-c-genotype-4-patients-a-randomized-controlled-trial
#9
Ibrahim H Altraif, Faisal Sanai, Mohammed A Babatin, Abduljaleel A Alalwan, Ayman A Abdo, Waleed Alhamoudi, Musthafa Peedikayil, Hamdan Alghamdi, Fahad Alsohaibani, Khalid A Alswat, Shazia Murtaza, Abdullah Alghamdi, Sara Altraif, Abdulrahman Aljumah, Fayaz A Handoo, Abdulkareem M AlBekairy, Hamad I Al-Ashgar, Mohammed Alquaiz, Mohammed A Alblawi, Waleed AlTamimi, Véronique Loustaud-Ratti, Pierre Marquett
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in both arms and females were 50.3% of the patients, 76.5% had minimal-moderate fibrosis (F0-2). Sustained virologic response (SVR) was achieved in 99 (54...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29135030/hepatitis-c-virus-clearance-in-older-adults
#10
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio, Angelo Andriulli
OBJECTIVES: To determine whether older adults with the hepatitis C virus (HCV) achieve a sustained viral response (SVR) after treatment with direct-acting antiviral therapy. PARTICIPANTS: Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). MEASUREMENTS: We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents (DAAs)...
November 14, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29134150/hcv-core-antigen-is-an-alternative-marker-to-hcv-rna-for-evaluating-active-hcv-infection-implications-for-improved-diagnostic-option-in-an-era-of-affordable-daas
#11
Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, Chompoonut Auphimai, Nipaporn Siripon, Sirapa Klinfueng, Pisit Tangkijvanich, Sompong Vongpunsawad, Yong Poovorawan
The core antigen of the hepatitis C virus (HCV Ag) presents an alternative marker to HCV RNA when screening patients for HCV viremia. This study sought to evaluate the utility of HCV Ag as a marker to assess active HCV infection in individuals residing in an HCV-endemic area. From 298 HCV-seropositive individuals evaluated for the presence of anti-HCV antibody, HCV Ag and HCV RNA, anti-HCV antibody was detected in 252 individuals (signal-to-cutoff ratios ≥5), HCV RNA was detected in 222 individuals (88%), and HCV Ag was reactive (≥3 fmol/L) in 220 individuals (87%)...
2017: PeerJ
https://www.readbyqxmd.com/read/29133244/real-world-effectiveness-of-8-weeks-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis-c
#12
Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, Gerlinde Teuber, Heike-Pfeiffer Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem
BACKGROUND AND AIMS: Ledipasvir/Sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the summary of product characteristics (SmPC), 8 weeks treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of 8 week regimen of LDV/SOF under real-world conditions available...
November 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29125670/use-of-a-hepatitis-c-virus-hcv-rna-positive-donor-in-a-treated-hcv-rna-negative-liver-transplant-recipient
#13
Isabel Campos-Varela, Eliana Z Agudelo, Monika Sarkar, John P Roberts, Norah A Terrault
The shortage of livers has led most transplant centers to use extended criteria donors. Hepatitis C virus (HCV) RNA-positive donors are typically not given to patients who have cleared HCV. A 64-year-old male with chronic hepatitis C, genotype 1b was listed for LT with hepatocellular carcinoma. While on the waiting list, the patient was treated with sofosbuvir, ledipasvir, and ribavirin and achieved an HCV RNA <15 IU/mL by week 10. At week 18 of a planned 24-week treatment course, the patient underwent deceased-donor LT and received an organ from an anti-HCV-positive donor...
November 10, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29123424/liver-related-morbidity-and-mortality-in-patients-with-chronic-hepatitis-c-and-cirrhosis-with-and-without-sustained-virologic-response
#14
Sofie Hallager, Steen Ladelund, Peer Brehm Christensen, Mette Kjær, Birgit Thorup Roege, Karin Elmegaard Grønbæk, Erika Belard, Toke S Barfod, Lone Galmstrup Madsen, Jan Gerstoft, Britta Tarp, Henrik Bygum Krarup, Nina Weis
Background: Chronic hepatitis C (CHC) causes liver cirrhosis in 5%-20% of patients, leading to increased morbidity and mortality. This study aimed to estimate liver-related morbidity and mortality among patients with CHC and cirrhosis in Denmark with and without antiviral treatment and sustained virologic response (SVR). Furthermore we aimed to estimate the rate of hepatocellular carcinoma (HCC) and decompensation associated with certain prognostic factors. Materials and methods: Patients with CHC and cirrhosis registered in the Danish Database for Hepatitis B and C were eligible...
2017: Clinical Epidemiology
https://www.readbyqxmd.com/read/29120906/efficacy-of-ledipasvir-sofosbuvir-plus-ribavirin-for-12-weeks-in-patients-with-chronic-hepatitis-c-genotype-3-and-compensated-liver-disease
#15
Stephan Moser, Karin Kozbial, Hermann Laferl, Angelika Schütz, Thomas Reiberger, Philipp Schwabl, Enisa Gutic, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Tobias Lang, Michael Schleicher, Petra Steindl-Munda, Hans Haltmayer, Peter Ferenci, Michael Gschwantler
INTRODUCTION: In the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this regimen in a real-life cohort from Austria. PATIENTS AND METHODS: A total of 55 patients with HCV-GT3 and compensated liver disease (20% treatment-experienced, 33% with cirrhosis, 7% with HIV coinfection) from four Austrian hepatitis centers received treatment with SOF/LDV+RBV for 12 weeks...
November 8, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29116287/peginterferon-still-has-a-place-in-the-treatment-of-hepatitis-c-caused-by-genotype-3-virus
#16
Aline Vitali Grando, Paulo Roberto Abrão Ferreira, Mário Guimarães Pessôa, Daniel Ferraz de Campos Mazo, Carlos Eduardo Brandão-Mello, Tânia Reuter, Ana de Lourdes Candolo Martinelli, Mário Peribanez Gonzalez, Ana Catharina Seixas-Santos Nastri, Aléia Faustina Campos, Max Igor Banks Ferreira Lopes, José David Urbaez Brito, Maria Cássia Mendes-Corrêa
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers...
November 6, 2017: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/29116219/a-comparative-study-on-the-characterization-of-hepatitis-b-virus-quasispecies-by-clone-based-sequencing-and-third-generation-sequencing
#17
Jing Li, Mingjie Wang, Demin Yu, Yue Han, Zhitao Yang, Lei Wang, Xinxin Zhang, Feng Liu
Hepatitis B virus (HBV) has a high mutation rate due to the extremely high replication rate and the proofreading deficiency during reverse transcription. The generated variants with genetic heterogeneity are described as viral quasispecies (QS). Clone-based sequencing (CBS) is thought to be the 'gold standard' for assessing QS complexity and diversity of HBV, but an important issue about CBS is cost-effectiveness and laborious. In this study, we investigated the utility of the third-generation sequencing (TGS) DNA sequencing to characterize genetic heterogeneity of HBV QS and assessed the possible contribution of TGS technology in HBV QS studies...
November 8, 2017: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/29115151/sofosbuvir-velpatasvir-voxilaprevir-a-pan-genotypic-direct-acting-antiviral-combination-for-hepatitis-c
#18
Elias B Chahine, Denise Kelley, Lindsey M Childs-Kean
OBJECTIVES: To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection. DATA SOURCES: A literature search through PubMed was conducted (August 2010 to August 2017) using the terms GS-9857, voxilaprevir, and NS3/4A protease inhibitor. STUDY SELECTION/DATA EXTRACTION: Studies of sofosbuvir/velpatasvir/voxilaprevir were identified. DATA SYNTHESIS: Sofosbuvir/velpatasvir/voxilaprevir is indicated for adult patients with chronic HCV without cirrhosis or with compensated cirrhosis who have (1) genotype 1 through 6 and have previously been treated with an NS5A inhibitor or (2) genotype 1a or 3 and have previously been treated with sofosbuvir without an NS5A inhibitor...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29113004/direct-acting-antiviral-agents-in-the-treatment-of-chronic-hepatitis-c-real-life-experience-from-an-academic-centre-and-two-specialized-clinical-practices
#19
Manuel Jonathan Groß, Georg Härter, Johanna Backhus, Eugen Zizer, Thomas Seufferlein, Leopold Ludwig, Nektarios Dikopoulos
The introduction of the new direct antiviral agents has revolutionized the therapy of chronic hepatitis C. Today we are able to cure the vast majority of our patients with an 8- to 12-week therapy course of an antiviral combination therapy with an excellent safety profile. Real-life data are very important to further develop our experience with the new therapeutics and help us to improve the care of our patients in our everyday clinical practice.In our study, we present the retrospective analysis of a representative German cohort of 344 patients with chronic hepatitis C treated with the new direct antiviral agents...
November 7, 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29111616/daclatasvir-and-asunaprevir-treatment-in-patients-infected-by-genotype-1b-of-hepatitis-c-virus-with-no-or-subtle-resistant-associated-substitutions-ras-in-ns5a-y93
#20
Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Yoshiki Hirooka, Hidemi Goto
(Backgrounds and Aims) In this study, we investigated the real-world data of the first approved interferon free regimen in Japan; daclatasvir and asunaprevir (DCV+ASV) in chronic hepatitis C patients infected HCV genotype 1b with no or subtle amount of baseline resistant associated substitutions (RAS). (Patients and Methods) Among 924 patients registered in our multicenter study, 750 patients that were proven not to be infected with NS5A-Y93H resistant associated substitutions (RAS) by direct sequencing and to have no or subtle amount (less than 20%) of NS5A-Y93H RAS by probe assays (Cycleave or PCR invader assay) were included in this study...
November 7, 2017: Journal of Medical Virology
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"